Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

SELURL PHARMACIE DU GRAND SAINT GINIEZ : revenue, balance sheet and financial ratios

SELURL PHARMACIE DU GRAND SAINT GINIEZ is a French company founded 15 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in MARSEILLE (13008), this company of category PME shows in 2025 a net income positive of 166 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SELURL PHARMACIE DU GRAND SAINT GINIEZ (SIREN 523212389)
Indicator 2025 2024 2023 2022 2020
Revenue N/C N/C N/C N/C N/C
Net income 166 315 € 113 325 € 178 167 € 236 080 € 141 428 €
EBITDA N/C N/C N/C N/C N/C
Net margin N/C N/C N/C N/C N/C

Revenue and income statement

In 2025, SELURL PHARMACIE DU GRAND SAINT GINIEZ generates positive net income of 166 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2020-2025: 141 k€ -> 166 k€.

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

166 315 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 78%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 50%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

78.27%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

49.619%

Solvency indicators evolution
SELURL PHARMACIE DU GRAND SAINT GINIEZ

Sector positioning

Debt ratio
78.27 2025
2023
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Average -6 pts over 3 years

In 2025, the debt ratio of SELURL PHARMACIE DU GRAND... (78.27) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
49.62% 2025
2023
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Average +7 pts over 3 years

In 2025, the financial autonomy of SELURL PHARMACIE DU GRAND... (49.6%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Positioning of SELURL PHARMACIE DU GRAND SAINT GINIEZ in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 277 transactions of similar company sales in 2025, the value of SELURL PHARMACIE DU GRAND SAINT GINIEZ is estimated at 2 641 933 € (range 1 792 828€ - 4 145 557€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2025
277 transactions
1792k€ 2641k€ 4145k€
2 641 933 € Range: 1 792 828€ - 4 145 557€
NAF 5 année 2025

Valuation method used

Net Income Multiple
166 315 € × 15.9x = 2 641 934 €
Range: 1 792 829€ - 4 145 558€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare SELURL PHARMACIE DU GRAND SAINT GINIEZ with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about SELURL PHARMACIE DU GRAND SAINT GINIEZ

What is the revenue of SELURL PHARMACIE DU GRAND SAINT GINIEZ ?

The revenue of SELURL PHARMACIE DU GRAND SAINT GINIEZ is not publicly disclosed (confidential accounts filed with INPI).

Is SELURL PHARMACIE DU GRAND SAINT GINIEZ profitable?

Yes, SELURL PHARMACIE DU GRAND SAINT GINIEZ generated a net profit of 166 k€ in 2025.

Where is the headquarters of SELURL PHARMACIE DU GRAND SAINT GINIEZ ?

The headquarters of SELURL PHARMACIE DU GRAND SAINT GINIEZ is located in MARSEILLE (13008), in the department Bouches-du-Rhone.

Where to find the tax return of SELURL PHARMACIE DU GRAND SAINT GINIEZ ?

The tax return of SELURL PHARMACIE DU GRAND SAINT GINIEZ is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SELURL PHARMACIE DU GRAND SAINT GINIEZ operate?

SELURL PHARMACIE DU GRAND SAINT GINIEZ operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.